Does Blue Cross Blue Shield of Michigan Cover Novolog?

How BCBSM Formulary Placement Works for Novolog

Blue Cross Blue Shield of Michigan organizes its drug formulary into tiers that determine your out-of-pocket cost. Novolog (insulin aspart), a rapid-acting insulin manufactured by Novo Nordisk, appears on most BCBSM formulary editions. Its exact tier placement shifts between plan years and product lines.

Understanding the Tier System

BCBSM commercial plans typically use a four- or five-tier structure. Tier 1 covers generics at the lowest copay. Tier 2 covers preferred brands. Tier 3 covers non-preferred brands, and specialty tiers apply to high-cost medications. Novolog most often lands on Tier 2 or Tier 3, depending on whether BCBSM's pharmacy benefit manager has negotiated preferred status with Novo Nordisk for a given plan year.

Checking Your Specific Plan

Not all BCBSM plans are identical. Employer-sponsored group plans, individual marketplace plans, and Medicare Advantage plans each maintain separate formularies. The BCBSM online formulary search tool at bcbsm.com lets members verify Novolog's tier placement by entering their member ID. The American Diabetes Association recommends that all patients with diabetes confirm formulary status before each plan year, since tier changes can alter costs by $20 to $50 per fill [1].

A 2023 analysis published in Diabetes Care found that 27.8% of commercially insured patients with type 1 diabetes reported switching insulin products at least once due to formulary changes over a three-year period [2]. Checking coverage proactively helps avoid unexpected pharmacy costs.

Novolog Copays and Out-of-Pocket Costs on BCBSM Plans

The price you pay at the pharmacy counter depends on your tier, deductible status, and whether you have met any out-of-pocket maximums. BCBSM publishes estimated cost ranges in its Summary of Benefits documents.

Commercial Plan Costs

For most BCBSM commercial plans, a Tier 2 preferred brand copay runs between $30 and $50 per 30-day supply. If Novolog sits on Tier 3, expect $50 to $80. Some high-deductible health plans (HDHPs) paired with HSAs require you to pay full price until the deductible is met, which can mean $150 to $300 per vial at retail pharmacy pricing.

Medicare Advantage and the $35 Insulin Cap

The Inflation Reduction Act of 2022 capped out-of-pocket insulin costs at $35 per month for Medicare Part D and Medicare Advantage enrollees, effective January 2023 [3]. BCBSM Medicare Advantage members who use Novolog benefit from this cap regardless of formulary tier. The Centers for Medicare & Medicaid Services (CMS) confirmed that the cap applies to all covered insulin products, including rapid-acting formulations like insulin aspart [4].

This represents a significant reduction. Before the cap, Medicare beneficiaries paid an average of $54.87 per insulin fill in 2022, according to a Kaiser Family Foundation analysis [5]. The cap saves many Novolog users $20 or more per monthly fill.

Mail-Order Savings

BCBSM members who fill a 90-day Novolog supply through a preferred mail-order pharmacy typically pay 2.0 to 2.5 times the 30-day copay rather than three times. That structure effectively gives you one month free for every three-month order. Contact BCBSM member services or log into your account to verify your plan's mail-order benefit.

Prior Authorization and Step Therapy Requirements

Prior authorization (PA) adds a layer of approval before the pharmacy can dispense a medication. Step therapy requires trying a lower-cost alternative first.

When PA Applies

Most BCBSM standard commercial plans do not require prior authorization for Novolog. The drug's long track record and FDA approval since 2000 [6] make it a well-established rapid-acting insulin. Some employer-customized plans and certain Medicare Advantage products do include PA requirements for brand-name insulins when a biosimilar or authorized generic is available at a lower tier.

Step Therapy Considerations

BCBSM may implement step therapy protocols that require members to try a preferred rapid-acting insulin before covering a non-preferred one. If Novolog is classified as non-preferred on your specific plan, you might need to trial Humalog (insulin lispro) or a biosimilar insulin aspart first. Your prescribing physician can submit a formulary exception request if clinical reasons justify Novolog specifically.

The Endocrine Society's 2024 clinical practice guideline on insulin therapy states: "Switching between rapid-acting insulin analogs should be done cautiously, with dose adjustment and glucose monitoring, as pharmacokinetic profiles differ slightly between products" [7].

Filing a Formulary Exception

If BCBSM denies Novolog coverage or places it at a higher tier than expected, you have the right to request a formulary exception. Your physician submits clinical documentation explaining medical necessity. Common reasons include adverse reactions to alternative insulins, documented glycemic instability on other products, or allergies to inactive ingredients in competing formulations. BCBSM must respond to standard exception requests within 72 hours for commercial plans and 24 hours for urgent Medicare requests [4].

Novolog vs. Biosimilar and Authorized Generic Options

The insulin market has changed rapidly. Several lower-cost alternatives to brand-name Novolog now exist, and BCBSM formularies increasingly favor them.

Authorized Generic Insulin Aspart

Novo Nordisk launched an authorized generic version of Novolog in 2020 at a list price roughly 50% lower than the brand [8]. This product is pharmaceutically identical to Novolog. BCBSM may list the authorized generic on a lower tier than brand Novolog, which means a smaller copay. Ask your pharmacist whether a substitution is available at your pharmacy.

Biosimilar Insulin Aspart

The FDA approved the first interchangeable biosimilar insulin aspart in 2024, allowing pharmacists in Michigan to substitute it at the counter without a new prescription in most cases [9]. Biosimilar insulins demonstrated equivalent glycemic control in clinical trials. The ONSET-1 trial (N=560) showed that biosimilar insulin aspart produced a change in HbA1c of -0.34% vs. -0.38% for Novolog, with the 95% confidence interval falling within the pre-specified equivalence margin [10].

How to Compare Costs

Call the number on the back of your BCBSM card and ask the representative to compare the copay for brand Novolog, the authorized generic, and any formulary-listed biosimilar. The price difference can be $15 to $40 per fill. Your physician can specify "dispense as written" if brand Novolog is medically necessary, but this may result in a higher copay.

Novolog Delivery Devices and Coverage Nuances

Novolog is available in multiple delivery forms: 10 mL vials, FlexPen prefilled pens, and PenFill cartridges for reusable pen devices. BCBSM coverage can vary by delivery format.

Vials vs. Pens

Vials are typically the least expensive option per unit of insulin. Pens carry a premium because of the convenience of the delivery device. On some BCBSM plans, Novolog pens may require a higher copay or sit on a different tier than vials. A 2022 study in the Journal of Managed Care & Specialty Pharmacy found that patients using insulin pens had 11% fewer hypoglycemic events compared to vial-and-syringe users, which offset some of the higher acquisition cost through reduced emergency utilization [11].

Insulin Pump Supplies

If you use Novolog in an insulin pump, coverage falls under your plan's durable medical equipment (DME) benefit rather than the pharmacy benefit. This distinction matters. DME benefits often have different deductibles, coinsurance rates, and prior authorization requirements. BCBSM members using pumps should verify whether Novolog cartridges for pump use are covered under pharmacy or DME, as the cost-sharing structure can differ significantly.

Dr. Irl Hirsch, professor of medicine at the University of Washington, has noted: "Insurance coverage for insulin should be evaluated as a total system cost, including the delivery device, monitoring supplies, and the insulin itself, rather than looking at any single component in isolation" [12].

Cost-Saving Strategies for Novolog on BCBSM

Even with insurance coverage, insulin costs add up over time. Several strategies can reduce your annual spending.

Novo Nordisk Patient Assistance Programs

Novo Nordisk offers the NovoCare patient assistance program for uninsured or underinsured patients. Eligible individuals can receive Novolog at no cost. For commercially insured patients, the Novo Nordisk copay savings card can reduce out-of-pocket costs to as little as $25 per 30-day supply, though this benefit does not apply to government-funded insurance like Medicare or Medicaid [13].

Michigan-Specific Resources

Michigan's Prescription Drug Assistance Program provides additional support for residents who meet income eligibility criteria. The Michigan Department of Health and Human Services maintains a list of pharmaceutical assistance programs. BCBSM also partners with community health organizations that offer insulin access programs in underserved areas of the state.

Pharmacy Shopping

Retail pharmacy prices for the same insulin can vary by 30% or more within a single zip code. GoodRx and similar tools show cash prices across pharmacies, which is useful if your plan requires meeting a deductible before coverage applies. BCBSM's preferred pharmacy network offers the lowest negotiated rates, so staying in-network is typically the most cost-effective approach.

340B Program Eligibility

Patients who receive care at Federally Qualified Health Centers (FQHCs) or other 340B-eligible entities in Michigan may access Novolog at significantly reduced prices through the federal 340B Drug Pricing Program [14]. This applies regardless of insurance status and can reduce insulin costs by 25% to 50% compared to standard retail pricing.

When BCBSM Denies Novolog Coverage

Denials happen. Understanding the appeals process makes the difference between paying full price and getting coverage restored.

Common Denial Reasons

The most frequent reasons BCBSM denies Novolog claims include: the medication is not on the member's specific formulary, step therapy requirements have not been met, the quantity requested exceeds plan limits, or prior authorization was not obtained when required. Each of these is addressable through the appeals process.

The Appeals Timeline

BCBSM provides a two-level internal appeals process for commercial plans. The first-level appeal must be filed within 180 days of the denial. BCBSM reviews the appeal within 30 calendar days for non-urgent requests. If the first appeal is denied, a second-level appeal goes to an independent review organization. Michigan law requires insurers to provide clear written explanations for all prescription drug denials [15].

External Review

After exhausting internal appeals, Michigan residents can request an external review through the Michigan Department of Insurance and Financial Services (DIFS). This independent review is binding on the insurer. The process is free to the member.

Comparing Novolog Coverage Across Michigan Insurers

BCBSM is the largest insurer in Michigan, covering approximately 4.4 million residents, but it is not the only option [16]. Priority Health, HAP (Health Alliance Plan), and Molina Healthcare also operate in the state. Novolog's formulary position varies across these carriers.

Competitive Formulary Positioning

During open enrollment, comparing Novolog coverage across available plans can save hundreds of dollars annually. The key data points to compare are: tier placement, copay or coinsurance amount, whether prior authorization is required, and whether the plan applies the $35 insulin cap voluntarily for commercial members (some insurers have adopted this cap even for non-Medicare plans).

A 2024 survey by the American Diabetes Association found that 32% of adults with diabetes reported rationing insulin due to cost at least once in the prior 12 months [1]. Choosing the right plan at enrollment is one of the most effective ways to prevent cost-driven rationing.